UPDATE: Citigroup Raises PT to $89 on DaVita - Benzinga PDF Print
Benzinga
By David Johnson Citigroup raises its price target on Neutral-rated DaVita (NYSE: DVA) to $89 from $87 on on broader market valuation considerations following the company's integrated care ESRD opportunity. Citigroup says, "We believe integrated care

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.